Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Furegrelate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | PIM1 | P11309 | 1/20 | 0.49 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.49 |
| ▸ | TBXAS1 | P24557 | 11/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Furegrelate SCHEMBL29439935 | 1.00 | KMT2A (1.00) | KMT2ACYP3A4MEN1TP53BLM | |
| Furegrelate SCHEMBL30530940 | 0.99 | KMT2A (0.98) | KMT2ACYP3A4MEN1TP53BLM | |
| SCHEMBL11069202 | 0.90 | KMT2A (0.82) | KMT2ACYP3A4MEN1TP53BLM | |
| Furegrelate SCHEMBL10953582 | 0.87 | TP53 (0.77) | KMT2ACYP3A4MEN1TP53BLM | |
| SCHEMBL10953960 | 0.87 | KMT2A (0.77) | KMT2ACYP3A4MEN1TP53BLM | |
| Furegrelate SCHEMBL10451458 | 0.86 | TP53 (0.76) | KMT2ACYP3A4MEN1TP53BLM | |
| Furegrelate SCHEMBL10956224 | 0.86 | TP53 (0.76) | KMT2ACYP3A4MEN1TP53BLM | |
| SCHEMBL30362902 | 0.83 | KMT2A (0.71) | KMT2ACYP3A4MEN1TP53BLM | |
| SCHEMBL28461381 | 0.83 | KMT2A (0.71) | KMT2ACYP3A4MEN1TP53BLM | |
| SCHEMBL10957358 | 0.81 | MEN1 (0.68) | KMT2ACYP3A4MEN1TP53BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 222 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120277178-A1 | COMPOSITIONS AND METHODS FOR TREATING FRAGILE X PREMUTATION RVGG REPEATS-MEDIATED TOXICITY | EMORY UNIVERSITY (US) | 2012-11-01 | — | — | US | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| EP-1920773-A1 | Compositions for inhibition of anglogenesis | The Children's Medical Center Corporation (US) | 2008-05-14 | — | — | EP | claimed |
| EP-1611238-A4 | GLUTAMATE TRANSPORT MODULATORY COMPOUNDS AND METHODS | UNIV JOHNS HOPKINS (US) | 2007-07-04 | — | — | EP | claimed |
| US-20060121488-A1 | Glutamate transport modulatory compounds and methods | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2006-06-08 | — | — | US | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| EP-1611238-A2 | GLUTAMATE TRANSPORT MODULATORY COMPOUNDS AND METHODS | Johns Hopkins University (US) | 2006-01-04 | — | — | EP | claimed |
| EP-1586322-A2 | Compositions for inhibition of anglogenesis | The Children's Medical Center Corporation (US) | 2005-10-19 | — | — | EP | claimed |
| EP-0963200-B1 | COMPOSITIONS FOR INHIBITION OF ANGIOGENESIS COMPRISING THALODOMIDE AND A NSAID | CHILDRENS MEDICAL CENTER (US) | 2005-09-28 | — | — | EP | claimed |
| US-20040248820-A1 | Methods and compositions for inhibition of angiogenesis | D AMATO ROBERT J (US) | 2004-12-09 | — | — | US | claimed |
| WO-2004076675-A2 | GLUTAMATE TRANSPORT MODULATORY COMPOUNDS AND METHODS | JOHNS HOPKINS UNIVERSITY (US) | 2004-09-10 | — | — | WO | claimed |
| US-20030191098-A1 | Methods and compositions for inhibition of angiogenesis | D AMATO ROBERT J (US) | 2003-10-09 | — | — | US | claimed |
| JP-2002513391-A | — | — | 2002-05-08 | — | — | JP | claimed |
| EP-0963200-A2 | METHODS AND COMPOSITIONS FOR INHIBITION OF ANGIOGENESIS | The Children's Medical Center Corporation (US) | 1999-12-15 | — | — | EP | claimed |
| WO-1998019649-A2 | METHODS AND COMPOSITIONS FOR INHIBITION OF ANGIOGENESIS | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 1998-05-14 | — | — | WO | claimed |
| US-4925869-A | REACTIVATING ENZYME ACETYLCHOLINESTERASE INHIBITED BY LETHAL DOSE OF SOMAN | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-05-15 | — | — | US | claimed |
| US-4908380-A | Substituted 1,3-dioxane ether derivative; thromboxane A2 inhibitor | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-03-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248820-A1 | Methods and compositions for inhibition of angiogenesis | PGF, PTGS1, PTGIS | KMT2A 3789/4885CYP3A4 716/4885MEN1 3741/4885 |
| US-20030191098-A1 | Methods and compositions for inhibition of angiogenesis | PGF, PTGS1, PTGIS | KMT2A 3789/4885CYP3A4 716/4885MEN1 3741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.